Optimi Health Corp.

424B4 priced

Price $6.25 · 2,400,000 shares · Gross proceeds $15,000,000

EFFECT effective

CERT inactive

8-A12B effective

F-1/A amended

Range $6.00 to $8.00 · 2,500,000 shares

Optimi Health Corp. focuses on psychedelic-assisted therapies, specializing in GMP psychedelic substances like MDMA and psilocybin. The filing highlights supply chain vulnerabilities, regulatory compliance risks, and reliance on strategic partnerships. Financial performance is impacted by operational costs, inventory impairments, and the winding down of a loss-making nutraceutical segment. The company emphasizes its need for capital to scale manufacturing and navigate U.S. regulatory shifts.

F-1/A amended

Range $6.00 to $8.00 · 2,500,000 shares

Optimi Health Corp. is conducting an initial public offering (IPO) of 2,500,000 common shares at an estimated price range of $6.00 to $8.00 per share. The offering includes underwriter warrants and potential over-allotment options. The company operates as a GMP-compliant pharmaceutical manufacturer licensed by Health Canada for controlled substances, with products including MDMA and psilocybin. It seeks to expand into regulated markets in Australia, Canada, and potential future jurisdictions, while navigating complex regulatory environments. A reverse share split (1-for-30) is planned to meet Nasdaq listing requirements.

F-1/A amended

Optimi Health Corp. filed Amendment No. 6 to its F-1 registration statement, adding an amended Filing Fee Table (Exhibit 107). The filing reflects an initial public offering of 2.5 million common shares, with underwriter warrants and potential over-allotment options. The company, an emerging growth company, plans a reverse share split to meet Nasdaq listing requirements. The offering price is expected to range between $6.00 and $8.00 per share, with proceeds intended for working capital and general corporate purposes.

F-1/A amended

Range $6.00 to $8.00 · 2,500,000 shares

Optimi Health Corp. is conducting an initial public offering (IPO) of 2,500,000 common shares, with an expected price range of $6.00 to $8.00 per share. The company, a Canadian pharmaceutical manufacturer specializing in controlled substances like MDMA and psilocybin, is seeking to list on Nasdaq under the symbol "OPTH." The offering includes registration of warrants and underwriter options, with a reverse share split (1-for-30) intended to meet Nasdaq's minimum share price requirements. The company operates under Health Canada licenses, enabling regulated production and export of psychedelic drugs, but faces significant regulatory and legal risks in the U.S. and other markets.

F-1/A amended

Range $6.00 to $8.00 · 2,500,000 shares · Gross proceeds $20,000,000

Optimi Health Corp. is conducting an initial public offering (IPO) of 2,500,000 units, each consisting of one common share and one warrant to purchase a common share. The offering aims to raise capital for expansion, with the company specializing in pharmaceutical production of controlled substances like MDMA and psilocybin under Canadian and international regulatory frameworks. The filing includes details on a reverse share split to meet Nasdaq listing requirements and highlights risks related to regulatory compliance, clinical trial outcomes, and market acceptance of psychedelic therapies.

F-1/A amended

Range $6.00 to $8.00 · 2,500,000 shares

Optimi Health Corp. is conducting an initial public offering (IPO) of 2,500,000 common shares in the U.S., with an expected price range of $6.00 to $8.00 per share. The offering includes underwriter warrants and up to 143,750 additional shares upon warrant exercise. The company seeks Nasdaq listing under the symbol 'OPTH' and has approved a 1-for-30 reverse share split to meet Nasdaq's minimum share price requirement. The filing highlights its GMP-compliant production of psychedelic drugs (MDMA, psilocybin) for regulated markets, with operations in Canada and planned expansions, while noting risks related to regulatory approvals and legal uncertainties around psychedelic substances.

F-1/A amended

Range $6.00 to $8.00 · 2,142,857 shares

Optimi Health Corp. is conducting an initial public offering (IPO) of 2,142,857 common shares in the U.S., with an expected price range of $6.00 to $8.00 per share. The company, a Canadian GMP-compliant pharmaceutical manufacturer, produces controlled substances like MDMA and psilocybin, licensed for distribution in Canada, Australia, and other markets. The filing includes registration of underwriter warrants and shares upon warrant exercise, a reverse share split to meet Nasdaq listing requirements, and details about the underwriter's option to purchase additional shares. The company faces regulatory risks due to the controlled status of its products in the U.S. and other jurisdictions.

F-1/A amended

Optimi Health Corp. is conducting an initial public offering (IPO) of common shares in the U.S., with an aggregate offering size yet to be specified. The company, a Canadian pharmaceutical manufacturer licensed for controlled substances, focuses on psychedelics like MDMA and psilocybin. The offering includes underwriter warrants and potential additional shares via an over-allotment option. The company aims to list on Nasdaq under the symbol 'OPTH' and has approved a reverse share split to meet listing requirements. The IPO follows existing listings on the Canadian Securities Exchange and Frankfurt Stock Exchange.

F-1 filed

Optimi Health Corp. is conducting an initial public offering (IPO) of common shares in the U.S., with an offering size of unspecified shares. The company, a Canadian pharmaceutical manufacturer licensed for controlled substances, produces psychedelic drugs like MDMA and psilocybin. It holds multiple regulatory licenses, including a Drug Establishment Licence (DEL) and Dealer’s Licence (DL), enabling supply in Canada, Australia, and through clinical trials in other jurisdictions. The IPO includes underwriter warrants and a potential reverse share split to meet Nasdaq listing requirements. The company is an emerging growth company with significant risks tied to regulatory approvals and the legal status of its products.

DRS/A amended

Optimi Health Corp. is conducting an initial public offering (IPO) of common shares in the U.S., with an anticipated price range of US$ to US$ per share. The company, a Canadian pharmaceutical manufacturer licensed for controlled substances, produces psychedelic drugs like MDMA and psilocybin. The offering includes underwriter warrants and an over-allotment option. The company plans a reverse share split to meet Nasdaq listing requirements and has applied for listing on the Nasdaq Capital Market. The filing highlights risks related to regulatory environments, U.S. restrictions on psychedelic drugs, and reliance on licenses for commercialization.

DRS filed

Optimi Health Corp. is conducting an initial public offering (IPO) of common shares in the U.S., with an aggregate offering size unspecified. The company, a Canadian pharmaceutical manufacturer specializing in controlled substances like MDMA and psilocybin, is seeking Nasdaq listing under the symbol "OPTH" following a reverse share split. Its operations are GMP-certified, with regulatory approvals for psychedelic drug production and export. The offering includes common shares, underwriter warrants, and potential over-allotment options. The company is an emerging growth company and foreign private issuer, with shares currently listed on the Canadian Securities Exchange (CSE) and OTCQX.